MARKET

SNY

SNY

Sanofi FR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.59
0.00
0.00%
After Hours: 46.59 0 0.00% 16:51 03/08 EST
OPEN
45.78
PREV CLOSE
46.59
HIGH
46.89
LOW
45.73
VOLUME
2.14M
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
37.62
MARKET CAP
116.54B
P/E (TTM)
7.79
1D
5D
1M
3M
1Y
5Y
Three Ways To Approach The Cannabis Trade
While many traders are looking to tech or pharma for the next big breakout, others are attempting to get in front of the market by trading an industry that is anticipated to grow to $20.6 billion by 2020. While cannabis isn’t entirely legal in the U.S., it...
Benzinga · 3d ago
Sanofi's (SNY) Dupixent sBLA for Asthma Gets FDA Acceptance
Zacks · 3d ago
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
Zacks.com · 4d ago
BRIEF-Sanofi Files U.S. Form 20-F, French “Document D’Enregistrement Universel” Containing FY Report
reuters.com · 4d ago
Filing of the 2020 U.S. Form 20-F and French Document dEnregistrement Universel containing the Annual Financial Report
GlobeNewswire · 4d ago
News From The Vaccine World
Less than a year before the COVID-19 started its relentless march across the globe Novavax (NASDAQ: NVAX) was facing delisting from the Nasdaq.
Benzinga · 4d ago
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)
Benzinga · 4d ago
Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review
The FDA has accepted for review the supplemental marketing application seeking approv
Benzinga · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNY. Analyze the recent business situations of Sanofi FR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNY stock price target is 64.67 with a high estimate of 69.00 and a low estimate of 58.50.
EPS
Institutional Holdings
Institutions: 872
Institutional Holdings: 178.74M
% Owned: 7.15%
Shares Outstanding: 2.50B
TypeInstitutionsShares
Increased
174
8.80M
New
136
-1.47M
Decreased
211
5.81M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.16%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Serge Weinberg
Chief Executive Officer/Executive Board/Director
Paul Hudson
Chief Financial Officer/Executive Vice President/Executive Board
Jean-Baptiste Chasseloup de Chatillon
Executive Vice President/General Counsel/Executive Board
Karen Linehan
Executive Vice President/Director of Human Resources/Executive Board
Caroline Luscombe
Executive Vice President/Executive Board
Olivier Charmeil
Executive Vice President/Executive Board
David Loew
Executive Vice President/Executive Board
Philippe Luscan
Executive Vice President/Executive Board
Alan Main
Executive Vice President/Executive Board
John Reed
Executive Vice President/Executive Board
William Sibold
Director
Laurent Attal
Director
Christophe Babule
Independent Director
Bernard Charles
Independent Director
Claudie Haignere
Independent Director
Patrick Kron
Independent Director
Fabienne Lecorvaisier
Independent Director
Melanie Lee
Independent Director
Suet-Fern Lee
Independent Director
Carole Piwnica
Independent Director
Suet Fern Lee
Independent Director
Gilles Schnepp
Independent Director
Diane Souza
Independent Director
Thomas Suedhof
Declaration Date
Dividend Per Share
Ex-Div Date
03/05/2020
Dividend USD 1.1735676
04/30/2020
--
Dividend USD 1.722322
05/07/2019
02/07/2018
Dividend USD 1.860874
05/09/2018
02/16/2017
Dividend USD 1.577088
05/11/2017
02/19/2016
Dividend USD 1.630252
05/05/2016
02/25/2015
Dividend USD 1.618087
05/06/2015
02/11/2014
Dividend USD 1.9096
05/07/2014
02/12/2013
Dividend USD 1.862409
05/06/2013
02/09/2012
Dividend USD 1.75642
05/07/2012
05/02/2011
Dividend USD 1.8221
05/11/2011
02/12/2010
Dividend USD 1.62732
05/17/2010
02/11/2009
Dividend USD 1.41856
04/20/2009
02/12/2008
Dividend USD 1.510272
05/16/2008
03/05/2007
Dividend USD 1.14537
06/04/2007
03/06/2006
Dividend USD 0.912
06/02/2006
03/01/2005
Dividend USD 0.7993
06/02/2005
09/02/2004
Dividend USD 0.0304
09/27/2004
--
Dividend USD 0.5795
04/30/2004
--
Dividend USD 0.4897
05/28/2003
About SNY
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Webull offers kinds of Sanofi SA (ADR) stock information, including NASDAQ:SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.